A novel mechanism to correct calcium channel dysfunction
Treating the
root cause of
RYR1-RM
RYR1-related myopathies are a group of muscle diseases caused by mutations in the RYR1 gene that lead to impaired muscle contraction and weakness. While current treatments are limited to supportive care, surlorian (ARM210) is a small molecule designed to address this underlying calcium channel dysfunction with the potential to improve muscle strength and functional outcomes.
Rycals®: Targeting a fundamental signaling pathway
Decades of foundational research have made it possible to drug ryanodine receptors (RyRs), ion channels that regulate the intracellular flow of calcium in nearly all cell types and are essential for muscle contraction.
We are a clinical-stage company developing a novel class of therapeutics, called Rycals®, for serious diseases with high unmet need in which ryanodine receptors play a critical role in disease progression. Our lead program is being developed to treat ryanodine receptor 1-related myopathies (RYR1-RM), a rare disease but the most common type of congenital myopathies.